Connect Biopharma (CNTB) News and press releases

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

22 Mar 23

Movers

Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

21 Mar 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

21 Mar 23

Movers

Why Cerberus Cyber Sentinel Shares Are Trading Higher By 147%; Here Are 20 Stocks Moving Premarket

21 Mar 23

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Cerberus Cyber Sentinel Corporation (NASDAQ: CISO) shares rose 147% to $0.5682 in pre-market trading. Cerberus Cyber Sentinel said it sees Q4 revenue of $14.7 million and sees FY22 revenue of $46.5 million.

Connect Biopharma's Atopic Dermatitis Candidate Shows Rapid, Sustained Improvement Across All Body Regions

20 Mar 23

Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD).

Connect Biopharma Announced CBP-201 Atopic Dermatitis China Pivotal Study Met Primary And Secondary Endpoints

18 Mar 23

News, Penny Stocks, Events

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

12 Health Care Stocks Moving In Friday's After-Market Session

17 Mar 23

Movers

Connect Biopharma Announced CBP-201 Global Phase 2 Asthma Trial Achieves Full Enrollment

9 Feb 23

News, Penny Stocks

Connect Biopharma Holdings Limited(Nasdaq: CNTB) today announced that itsCBP-201Phase 2 global trial in patients withmoderate-to-severeasthma with Type 2 inflammation(WW002)has reached its full targeted enrollment of 306 patients.

SVB Leerink Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $7

8 Feb 23

News, Price Target, Analyst Ratings

SVB Leerink analyst Thomas Smith maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $9 to $7.

Connect Biopharma Provides Business And Clinical Development Program Update

30 Dec 22

News

Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today provided a

Thinking about buying stock in First Republic Bank, Bank of America, Riot Platforms, Connect Biopharma, or General Motors?

20 Mar 23

Opinion, Press Releases

NEW YORK, March 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FRC, BAC, RIOT, CNTB, and GM.

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

18 Mar 23

Press Releases

Late-Breaking Abstract and Oral Presentation at American Academy of Dermatology Annual Meeting Stage 1 of ongoing 52-week China pivotal AD trial met primary and secondary endpoints No efficacy plateau at Week

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

17 Mar 23

Press Releases

ePoster and Oral Presentation at American Academy of Dermatology Annual Meeting Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

6 Mar 23

Press Releases

CBP-201 global AD data accepted as an e-Poster with an Oral Presentation CBP-201 China AD trial data accepted as a late-breaking Oral Presentation Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma or

Connect Biopharma Provides Business and Clinical Development Program Update

30 Dec 22

Health Care, Press Releases

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential